InMed becomes Mentari Therapeutics as migraine antibody pipeline takes centre stage
The completed merger gives the renamed US company a PACAP-targeting migraine prevention antibody in early clinical testing, with a bispecific follow-on heading towards a regulatory filing.
InMed Pharmaceuticals Inc. has finished combining with Mentari Therapeutics and now trades under the Mentari Therapeutics, Inc. name. The deal completed on 6 November 2026, according to the management's discussion and analysis the company filed with its Form 8-K.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.